• +1-646-491-9876
    • +91-20-67278686

    Search

    Male Hypogonadism - Pipeline Review, H1 2017

    Male Hypogonadism - Pipeline Review, H1 2017

    • Report Code ID: RW0001689457
    • Category Healthcare
    • No. of Pages 104
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H1 2017, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

    Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 1, 4, 7, 2, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

    Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
    - The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Male Hypogonadism - Overview
    Male Hypogonadism - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Male Hypogonadism - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Male Hypogonadism - Companies Involved in Therapeutics Development
    Antares Pharma Inc
    Clarus Therapeutics Inc
    EndoCeutics Inc
    Ferring International Center SA
    IASO BioMed Inc
    Lipocine Inc
    M et P Pharma AG
    Medlab Clinical Ltd
    Merck & Co Inc
    Mereo Biopharma Group Plc
    Pantarhei Bioscience BV
    Repros Therapeutics Inc
    Takeda Pharmaceutical Company Ltd
    TesoRx Pharma LLC
    Viramal Ltd
    Male Hypogonadism - Drug Profiles
    BGS-649 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    corifollitropin alfa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    enclomiphene citrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IAS-167A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Kisspeptin-10 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    leuprolide acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Libidua - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LPCN-1111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MSS-722 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    T-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-448 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone enanthate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone propionate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone undecanoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone undecanoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone undecanoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone undecanoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone undecanoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone undecanoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    testosterone undecanoate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Male Hypogonadism - Dormant Projects
    Male Hypogonadism - Discontinued Products
    Male Hypogonadism - Product Development Milestones
    Featured News & Press Releases
    Feb 08, 2017: Acerus Announces NATESTO Posters to Be Presented at the Endocrine Society 2017 Annual Meeting
    Feb 01, 2017: Aytu BioScience Announces Two Presentations at Endocrine Society 2017 Annual Meeting Highlighting Benefits of Natesto (Testosterone) Nasal Gel in Men
    Jan 24, 2017: Acerus Announces Natesto Abstracts To Be Presented At The American Urological Associations Annual Meeting
    Jan 18, 2017: Aytu BioScience Announces Two Presentations Highlighting Benefits of Natesto (Testosterone) Nasal Gel in Men at American Urological Association Annual Meeting
    Dec 21, 2016: Antares Pharma Announces Submission of New Drug Application for Quickshot Testosterone
    Dec 06, 2016: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism
    Nov 30, 2016: Aytu BioScience Announces Study Findings Demonstrating Clinical Improvements in Erectile Function and Mood in Hypogonadal Men Treated with Natesto Nasal Testosterone Gel
    Nov 21, 2016: Diurnal Group: First patient dosed in testosterone replacement therapy for hypogonadism
    Nov 02, 2016: Antares Pharma Announces Presentations at the Sexual Medicine Society Scientific Annual Meeting
    Oct 28, 2016: Antares Pharma Announces Multiple Presentations at the Sexual Medicine Society Scientific Annual Meeting
    Oct 05, 2016: Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities
    Oct 05, 2016: Acerus Announces Canadian Commercial Launch of NATESTO
    Sep 26, 2016: Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy
    Sep 22, 2016: Antares Pharma Announces Completion of the QuickShot Testosterone Clinical Program
    Sep 12, 2016: Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Male Hypogonadism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Male Hypogonadism - Pipeline by Antares Pharma Inc, H1 2017
    Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H1 2017
    Male Hypogonadism - Pipeline by EndoCeutics Inc, H1 2017
    Male Hypogonadism - Pipeline by Ferring International Center SA, H1 2017
    Male Hypogonadism - Pipeline by IASO BioMed Inc, H1 2017
    Male Hypogonadism - Pipeline by Lipocine Inc, H1 2017
    Male Hypogonadism - Pipeline by M et P Pharma AG, H1 2017
    Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H1 2017
    Male Hypogonadism - Pipeline by Merck & Co Inc, H1 2017
    Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H1 2017
    Male Hypogonadism - Pipeline by Pantarhei Bioscience BV, H1 2017
    Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H1 2017
    Male Hypogonadism - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H1 2017
    Male Hypogonadism - Pipeline by Viramal Ltd, H1 2017
    Male Hypogonadism - Dormant Projects, H1 2017
    Male Hypogonadism - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Male Hypogonadism, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Antares Pharma Inc
    Clarus Therapeutics Inc
    EndoCeutics Inc
    Ferring International Center SA
    IASO BioMed Inc
    Lipocine Inc
    M et P Pharma AG
    Medlab Clinical Ltd
    Merck & Co Inc
    Mereo Biopharma Group Plc
    Pantarhei Bioscience BV
    Repros Therapeutics Inc
    Takeda Pharmaceutical Company Ltd
    TesoRx Pharma LLC
    Viramal Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//male-hypogonadism-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//male-hypogonadism-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//male-hypogonadism-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments